Long-term protection after fractional-dose yellow fever vaccination follow-up study of a randomized, controlled, noninferiority trial

Annals of Internal Medicine

Volumn 169, Issue 11, 2018, Pages 761-765

  Roukens, Anna H E ^a   Van Halem, Karlijn ^a   De Visser, Adriëtte W ^a   Visser, Leo G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON-INFERIORITY TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; VACCINATION; YELLOW FEVER; BLOOD; EQUIVALENCE TRIAL (TOPIC); IMMUNOLOGY; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EQUIVALENCE TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 85057990261     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M18-1529     Document Type: Article

References (16)

1. Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec. 2013;88:269-83. [PMID: 23909008]
2. Shearer FM, Moyes CL, Pigott DM, Brady OJ, Marinho F, Desh-pande A, et al. Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis. Lancet Infect Dis. 2017; 17:1209-17. [PMID: 28822780] doi:10.1016/S1473-3099(17)30419-X
3. World Health Organization. Situation Report: Yellow Fever. Geneva: World Health Organization; 28 October 2016. Accessed at http://apps.who.int/iris/bitstream/10665/250661/1/yellowfeversitrep28Oct16-eng.pdf?ua=1 on 1 May 2018.
4. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled noninferiority trial. PLoS One. 2008;3:e1993. [PMID: 18431480] doi:10 .1371/journal.pone.0001993
5. Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, Peruhype-Magalhães V, Villela-Rezende G, Quaresma PF, et al. Sub-doses of 17DD yellow fever vaccine elicit equivalent virological immunological kinetics timeline. BMC Infect Dis. 2014;14:391. [PMID: 25022840] doi:10.1186/1471-2334-14-391
6. World Health Organization. Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response. WHO Secretariat Information Paper. Geneva: World Health Organization; 20 July 2016. Accessed at http://apps.who.int/iris/bitstream/10665/246236/1/WHO-YF-SAGE-16.1-eng.pdf?ua=1 on 3 October 2018.
7. Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak—preliminary report. N Engl J Med. 2018. [PMID: 29443626] doi:10.1056/NEJMoa1710430
8. Pan American Health Organization; World Health Organization. Epidemiological Update: Yellow Fever. Washington, DC: Pan American Health Organization; 20 March 2018. Accessed at www.paho.org/hq/index.php?option=com_content&view=article&id=14207: 20-march-2018-yellow-fever-epidemiological-update&Itemid= 42346&lang=en on 3 October 2018.
9. Pan American Health Organization. Brazil launches world's largest campaign with fractional-dose yellow fever vaccine. 25 January 2018. Accessed at www.paho.org/hq/index.php?option=com_content&view=article&id=14065%3Abrazil-launches-worlds-largest-campaign-with-fractional-dose-yellow-fever-vaccine&catid=1443% 3Aweb-bulletins&Itemid=135&lang=en on 1 May 2018.
10. Yellow fever vaccine: WHO position on the use of fractional doses – June 2017. Wkly Epidemiol Rec. 2017;92:345-50. [PMID: 28643507]
11. de Menezes Martins R, Maia MLS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, et al; Collaborative Group for Studies on Duration of Immunity from Yellow Fever Vaccine. Duration of postvaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine. 2018;36:4112-7. [PMID: 29784469] doi:10.1016/j.vaccine.2018.05.041
12. De Madrid AT, Porterfield JS. A simple micro-culture method for the study of group B arboviruses. Bull World Health Organ. 1969;40: 113-21. [PMID: 4183812]
13. Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS One. 2016;11:e0149871. [PMID: 26977808] doi:10.1371/journal .pone.0149871
14. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol. 1973;25:539-44. [PMID: 4633476]
15. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci. 2001;16:101-17.
16. World Health Organization. Meeting Report: WHO Informal Consultation of the Minimum Potency Specification for Yellow Fever Vaccines. National Institute for Biological Standards and Control, Potters Bar, United Kingdom, 19–20 November 2007.